SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
____________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): ~~May~~June 294, 2024

Skinvisible, Inc.
(Exact name of registrant as specified in its charter)

Nevada

000-25911

88-0344219

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)


6320 South Sandhill Road Suite 9, Las Vegas, NV	89120
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 702-433-7154

___________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	[ ]	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

	[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

SECTION 73 –- ~~Regulation~~SECURITIES FDAND ~~Disclosure~~TRADING MARKETS

Item 73.0102 ~~Regulation~~Unregistered FDSales ~~Disclosure~~of Equity Securities

On ~~May~~June 294, 2024, we issued a ~~press~~total ~~release concerning the filing~~ of ~~our~~350,000 ~~Provisional~~units ~~Patent~~to ~~Application with the US Patent & Trademark Office~~accredited ~~entitled~~investors, ~~“Transdermal~~where ~~Delivery~~each ~~Composition~~unit ~~for~~was ~~Delivery~~priced ofat ~~CB-1~~$0.10 ~~Receptor~~per ~~Antagonists~~unit and~~/or~~ ~~GLP-1~~consists ~~Receptor~~of ~~Agonists,~~one ~~and~~share ~~Method~~ of ~~Delivery,"~~common ~~covering~~stock ~~formulations~~in ~~that~~the ~~leverage~~company ~~our~~and ~~proprietary~~a ~~delivery~~warrant ~~technology~~to purchase ~~Invisicare~~one-half ~~for~~of ~~the~~one ~~transdermal~~share ~~administration~~ of ~~obesity~~common ~~drugs,~~stock ain ~~copy~~the ofcompany, ~~which~~exercisable isfor ~~attached~~one asyear ~~Exhibit~~from ~~99.1~~issuance towith ~~this~~an ~~Current~~exercise ~~Report~~price onat $0.20 ~~Form~~per ~~8-K~~share.

~~The~~These ~~information in~~securities ~~Item~~were ~~7.01~~issued pursuant to Section 4(2) of ~~this~~the ~~Current~~Securities Act ~~Report~~and/or onRule ~~Form~~506 ~~8-K~~and/or ~~(including~~Regulation ~~Exhibit~~S 99promulgated thereunder.1) ~~shall~~The ~~not~~investor berepresented ~~deemed~~the ~~“filed”~~intention ~~for~~to ~~purposes~~acquire ofthe ~~Section 18~~securities offor ~~the~~investment only ~~Securities~~and ~~Exchange~~not ~~Act~~with ofa ~~1934~~view ~~(the~~towards ~~“Exchange~~distribution. ~~Act”)~~The orinvestor ~~otherwise~~was ~~subject~~given toadequate ~~the~~information ~~liabilities~~about ofus ~~that~~to ~~section,~~make ~~nor shall~~an itinformed beinvestment ~~deemed~~decision. We ~~incorporated~~did bynot ~~reference~~engage in any ~~filing~~general ~~under~~solicitation ~~the~~or ~~Securities~~advertising. ~~Act~~We ofdirected ~~1933~~our ortransfer ~~the~~agent ~~Exchange~~to ~~Act,~~issue ~~except~~the asstock ~~expressly set~~certificates ~~forth~~with bythe appropriate ~~specific~~restrictive ~~reference~~legend inaffixed ~~such~~to athe ~~filing~~restricted stock.

~~SECTION 9 – Financial Statements and Exhibits~~2

~~Item 9.01 Financial Statements and Exhibits.~~SIGNATURES

Exhibit No.	Description
99.1	Press Release, dated May 29, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2Skinvisible, Inc.

~~SIGNATURES~~/s/ Terry Howlett

~~Pursuant~~Terry ~~to the requirements of the Securities Exchange Act of 1934, the~~Howlett ~~registrant~~Chief ~~has~~Executive ~~duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~Officer

~~Skinvisible~~Date: June 4, ~~Inc.~~2024

~~/s/ Terry Howlett~~3

Terry Howlett Chief Executive Officer

Date: May 29, 2024

Filing Compare · SKINVISIBLE, INC.